Yahoo Web Search

Search results

  1. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares of the newly combined company and $10.50 in cash for each share of Schering-Plough. Each Merck common ...

  2. Mar 10, 2009 · For more information about how we use your data, please refer to our privacy and cookie policies. Merck on Monday announced an agreed $41bn takeover of its New Jersey rival, Schering-Plough, just ...

    • Gwen Robinson
  3. Mar 9, 2009 · Resize. BOSTON (MarketWatch) -- Merck & Co. and Schering-Plough Corp. said Monday they plan to merge in a deal worth more than $41 billion as part of an effort to create a pharmaceutical giant ...

  4. Mar 9, 2009 · Schering-Plough shareholders will receive 0.5767 of a Merck share and $10.50 in cash for each share in a deal which values the US company’s equity at $41.1bn, or $23.61 a share. The price ...

  5. Nov 12, 2009 · Merck & Co. Inc. has officially acquired Schering-Plough and its subsidiary Intervet/Schering-Plough Animal Health. The companies began combined operations on Nov. 4. Merck, which sold its 50 percent of Merial Ltd. to joint venture parnter Sanofi-Aventis on Sept. 18, first announced its intentions to acquire the Kenilworth, N.J.-based company for $41.1 billion in early March. Richard Clark ...

  6. Mar 9, 2009 · Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.

  7. People also ask

  8. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. This price represents a premium to Schering-Plough shareholders of approximately 34 percent based on the closing price of Schering-Plough stock on March 6, 2009.

  1. People also search for